Drug Profile

BT 7401

Alternative Names: BT-7401

Latest Information Update: 04 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bicycle Therapeutics
Class Antineoplastics; Bicyclic peptides; Small molecules
Mechanism of Action CD137 antigen agonists; Cytotoxic T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Feb 2024 BT 7401 is still in preclinical trials for Cancer in United Kingdom
08 Jan 2020 Bicycle Therapeutics and Cancer Research UK plan a phase I/IIa trial for Cancer
08 Jan 2020 Bicycle Therapeutics and Cancer Research UK enters into Clinical Development Partnerships agreement for BT 7401 and 'Bicycle retains the right to advance the BT 7401 program Bicycle retains the right to advance the BT 7401 program further

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com